Journal article
Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel
Abstract
BACKGROUND: The genetic determinants of response to clopidogrel and aspirin are incompletely characterized. Recently, PEAR1 (platelet endothelial aggregation receptor-1) rs12041331 polymorphism has been shown to influence the platelet reactivity, but its impact on cardiovascular outcomes remains unclear in patients treated with antiplatelet agents.
METHODS AND RESULTS: In this prospective cohort study, 2439 Chinese patients with acute coronary …
Authors
Xu K; Ye S; Zhang S; Yang M; Zhu T; Kong D; Chen J; Xu L; Li J; Zhu H
Journal
Circulation Cardiovascular Interventions, Vol. 12, No. 5,
Publisher
Wolters Kluwer
Publication Date
May 2019
DOI
10.1161/circinterventions.118.007019
ISSN
1941-7640
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Acute Coronary SyndromeAgedAspirinChinaClopidogrelCoronary Artery DiseaseDrug ResistanceFemaleHomozygoteHumansMaleMiddle AgedPercutaneous Coronary InterventionPharmacogenomic VariantsPlatelet AggregationPlatelet Aggregation InhibitorsProspective StudiesReceptors, Cell SurfaceRisk AssessmentRisk FactorsStentsTime FactorsTreatment Outcome